Global NIPT Market
1. An Outline of the Global NIPT Market
1.1. Market Definition and Segmentation
1.2. Study Assumptions and Abbreviations
2. Research Methodology & Approach
2.1. Primary Research
2.2. Secondary Research
2.3. Data Triangulation
2.4. SPSS Methodology
3. Executive Summary
4. Growth Drivers
5. Major Roadblocks
6. Opportunities
7. Prevalent Trends
8. Government Regulation
9. Growth Outlook
10. Competitive White Space Analysis – Identifying Untapped Market Gaps
11. Risk Overview
12. SWOT
13. Technological Advancement
14. Technology Maturity Matrix for the NIPT Market: Recent News
15. Regional Demand
16. Global NIPT by Geography – Strategic Comparative Analysis
17. Strategic Segment Analysis: NIPT Demand Landscape
18. NIPT Demand Trends Driven by advancements in next-generation sequencing technologies, expanding prenatal screening programs, and growing awareness of early prenatal genetic testing. (2025-2037)
19. Root Cause Analysis (RCA) for discovering problems of the NIPT Market
20. Porter Five Forces
21. PESTLE
22. Comparative Positioning
23. Global NIPT – Key Player Analysis (2037)
24. Competitive Landscape: Key Suppliers/Players
25. Competitive Model: A Detailed Inside View for Investors
26. Company Market Share, 2037 (%)
26.1. Centogene N.V.
26.2. CRIFM Prenatal Medical Clinic
26.3. Eurofins LifeCodexx GmbH
26.4. MedGenome Labs Ltd.
26.5. NIPT Hiro Clinic
26.6. FALCO biosystems Ltd.
26.7. Biora Therapeutics, Inc. (formerly Progenity, Inc.)
26.8. F. Hoffmann-La Roche Ltd.
26.9. Illumina Inc.
26.10. Laboratory Corporation of America Holdings (Labcorp)
26.11. Natera Inc.
26.12. Myriad Women's Health, Inc.
26.13. QIAGEN
26.14. Quest Diagnostics
26.15. CooperSurgical, Inc.
26.16. Agilent Technologies, Inc.
26.17. Baylor Genetics
26.18. BGI
26.19. Lilac Insights
26.20. Neuberg Center for Genomic Medicine
26.21. Next Bioscience
26.22. Progenics
26.23. Sonic Healthcare
26.24. Thermo Fisher Scientific Inc.
26.25. Yourgene Health (Novacyt).
27. Global NIPT Market Outlook
27.1. Market Overview
27.1.1. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
27.2. NIPT Market Segmentation Analysis (2025-2037)
27.2.1. By Product
27.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
27.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
27.2.2. By Application
27.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
27.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
27.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
27.2.3. By Technology
27.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
27.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
27.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
27.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
27.2.4. By Pregnancy Risk
27.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
27.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
27.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
27.2.5. By End user
27.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
27.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
27.2.6. By Method
27.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
27.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
27.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
27.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
27.2.7. By Gestational Age
27.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
27.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
27.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
27.2.8. Regional Synopsis, Value (USD Million), 2025-2037
27.2.8.1. North America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
27.2.8.2. Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
27.2.8.3. Asia Pacific, excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
27.2.8.4. Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
27.2.8.5. Middle East and Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
28. North America Market
28.1. Overview
28.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
28.1.2. Increment $ Opportunity Assessment, 2025-2037
28.2. Segmentation (USD Million), 2025-2037, By
28.2.1. By Product
28.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
28.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
28.2.2. By Application
28.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
28.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
28.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
28.2.3. By Technology
28.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
28.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
28.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
28.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
28.2.4. By Pregnancy Risk
28.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
28.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
28.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
28.2.5. By End user
28.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
28.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
28.2.6. By Method
28.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
28.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
28.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
28.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
28.2.7. By Gestational Age
28.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
28.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
28.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
28.2.8. Country Level Analysis, Value (USD Million)
28.2.8.1. U.S. Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
28.2.8.2. Canada Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29. Europe Market
29.1. Overview
29.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
29.1.2. Increment $ Opportunity Assessment, 2025-2037
29.2. Segmentation (USD Million), 2025-2037, By
29.2.1. By Product
29.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
29.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
29.2.2. By Application
29.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
29.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
29.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
29.2.3. By Technology
29.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
29.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
29.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
29.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
29.2.4. By Pregnancy Risk
29.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
29.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
29.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
29.2.5. By End user
29.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
29.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
29.2.6. By Method
29.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
29.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
29.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
29.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
29.2.7. By Gestational Age
29.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
29.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
29.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
29.2.8. Country Level Analysis, Value (USD Million)
29.2.8.1. UK Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.2. Germany Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.3. France Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.4. Italy Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.5. Spain Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.6. Netherlands Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.7. Russia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.8. Switzerland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.9. Poland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.10. Belgium Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
29.2.8.11. Rest of Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30. Asia Pacific, excluding Japan Market
30.1. Overview
30.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
30.1.2. Increment $ Opportunity Assessment, 2025-2037
30.2. Segmentation (USD Million), 2025-2037, By
30.2.1. By Product
30.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
30.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
30.2.2. By Application
30.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
30.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
30.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
30.2.3. By Technology
30.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
30.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
30.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
30.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
30.2.4. By Pregnancy Risk
30.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
30.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
30.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
30.2.5. By End user
30.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
30.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
30.2.6. By Method
30.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
30.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
30.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
30.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
30.2.7. By Gestational Age
30.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
30.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
30.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
30.2.8. Country Level Analysis, Value (USD Million)
30.2.8.1. China Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.2. India Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.3. South Korea Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.4. Australia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.5. Indonesia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.6. Malaysia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.7. Vietnam Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.8. Thailand Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.9. Singapore Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.10. New Zealand Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
30.2.8.11. Rest of Asia Pacific Excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
31. Latin America Market
31.1. Overview
31.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
31.1.2. Increment $ Opportunity Assessment, 2025-2037
31.1.3. Year-on-Year Growth Forecast (%)
31.2. Segmentation (USD Million), 2025-2037, By
31.2.1. By Product
31.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
31.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
31.2.2. By Application
31.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
31.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
31.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
31.2.3. By Technology
31.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
31.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
31.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
31.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
31.2.4. By Pregnancy Risk
31.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
31.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
31.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
31.2.5. By End user
31.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
31.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
31.2.6. By Method
31.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
31.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
31.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
31.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
31.2.7. By Gestational Age
31.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
31.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
31.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
31.2.8. Country Level Analysis, Value (USD Million)
31.2.8.1. Brazil Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
31.2.8.2. Argentina Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
31.2.8.3. Mexico Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
31.2.8.4. Rest of Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32. Middle East & Africa Market
32.1. Overview
32.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
32.1.2. Increment $ Opportunity Assessment, 2025-2037
32.1.3. Year-on-Year Growth Forecast (%)
32.2. Segmentation (USD Million), 2025-2037, By
32.2.1. By Product
32.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
32.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
32.2.2. By Application
32.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
32.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
32.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
32.2.3. By Technology
32.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
32.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
32.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
32.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
32.2.4. By Pregnancy Risk
32.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
32.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
32.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
32.2.5. By End user
32.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
32.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
32.2.6. By Method
32.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
32.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
32.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
32.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
32.2.7. By Gestational Age
32.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
32.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
32.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
32.2.8. Country Level Analysis, Value (USD Million)
32.2.8.1. Saudi Arabia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.2. UAE Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.3. Israel Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.4. Qatar Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.5. Kuwait Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.6. Oman Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.7. South Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
32.2.8.8. Rest of Middle East & Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2025-2037F
33. Japan Market
33.1. Overview
33.1.1. Market Value (USD Million), Current and Future Projections, 2025-2037
33.1.2. Increment $ Opportunity Assessment, 2025-2037
33.1.3. Year-on-Year Growth Forecast (%)
33.2. Segmentation (USD Million), 2025-2037, By
33.2.1. By Product
33.2.1.1. Consumables, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1. Reagents, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1.1. cfDNA Extraction Reagents, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1.2. Library Preparation Reagents, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1.3. PCR Reagents & Master Mixes, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1.4. Sequencing Reagents, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.1.5. Others, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.1.2. Disposables, Market Value (USD Million), and CAGR, 2025-2037F
33.2.1.2. Instrument/Devices, Market Value (USD Million), and CAGR, 2025-2037F
33.2.2. By Application
33.2.2.1. Trisomy, Market Value (USD Million), and CAGR, 2025-2037F
33.2.2.2. Microdeletion Syndrome, Market Value (USD Million), and CAGR, 2025-2037F
33.2.2.3. Others, Market Value (USD Million), and CAGR, 2025-2037F
33.2.3. By Technology
33.2.3.1. Next-Generation Sequencing (NGS), Market Value (USD Million), and CAGR, 2025-2037F
33.2.3.2. Array Technology, Market Value (USD Million), and CAGR, 2025-2037F
33.2.3.3. Polymerase Chain Reaction (PCR), Market Value (USD Million), and CAGR, 2025-2037F
33.2.3.4. Others, Market Value (USD Million), and CAGR, 2025-2037F
33.2.4. By Pregnancy Risk
33.2.4.1. High-Risk, Market Value (USD Million), and CAGR, 2025-2037F
33.2.4.2. Average-Risk, Market Value (USD Million), and CAGR, 2025-2037F
33.2.4.3. Low-Risk, Market Value (USD Million), and CAGR, 2025-2037F
33.2.5. By End user
33.2.5.1. Diagnostic Laboratories, Market Value (USD Million), and CAGR, 2025-2037F
33.2.5.2. Hospitals & Clinics, Market Value (USD Million), and CAGR, 2025-2037F
33.2.6. By Method
33.2.6.1. Biochemical Screening Tests, Market Value (USD Million), and CAGR, 2025-2037F
33.2.6.2. Maternal cell-free DNA, Market Value (USD Million), and CAGR, 2025-2037F
33.2.6.3. Plasma Testing, Market Value (USD Million), and CAGR, 2025-2037F
33.2.6.4. Ultrasonic Detection, Market Value (USD Million), and CAGR, 2025-2037F
33.2.7. By Gestational Age
33.2.7.1. 0-12 weeks, Market Value (USD Million), and CAGR, 2025-2037F
33.2.7.2. 13-24 weeks, Market Value (USD Million), and CAGR, 2025-2037F
33.2.7.3. 25–36 weeks, Market Value (USD Million), and CAGR, 2025-2037F
34. Global Economic Scenario
34.1. World Economic Outlook
35. About Research Nester
35.1. Our Global Clientele
35.2. We Serve Clients Across World
Non-Invasive Prenatal Testing (NIPT) Market Outlook:
Non-Invasive Prenatal Testing (NIPT) Market size is valued at USD 4.53 billion in 2024 and is projected to reach USD 14.59 billion by 2037, growing at a CAGR of 9.42% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-invasive prenatal testing is evaluated at USD 4.95 billion.
The growing prevalence and recognition of chromosomal disorders is propelling the sales of non-invasive prenatal testing (NIPT) solutions. The most common fetal chromosomal abnormalities screened during pregnancy are Down syndrome, Edwards syndrome, and Patau syndrome. The likelihood of these conditions boosts the need for advanced non-invasive prenatal testing technologies.
The World Health Organization (WHO) disclosed that around 7.9 million babies, or about 6% of all births each year, are born with genetic or partly genetic conditions. The Eastern Mediterranean Region carries a large share of this burden, with some countries and communities showing very high rates of blood disorders as much as 26% such as thalassemia and sickle cell disease. In some places, these conditions are also linked to marriage between relatives. Thus, the growth in genetic disorders is estimated to offer high-earning opportunities to NIPT manufacturers.
Cost-Effectiveness of NIPT vs. Direct Amniocentesis
Brazilian Private Healthcare System (Payer Perspective)
|
Metric |
Value (IntI $) |
Value (BRL) |
Notes |
|
Incremental Cost (NIPT strategy vs. Amniocentesis) |
4,874.52 |
2,790.99 |
Per patient per year |
|
Incremental Cost per QALY (ICER) |
34,064.44 |
21,453.96 |
Base case |
|
Reduction in Amniocenteses |
-18.4% |
-18.4% |
Annual |
|
Reduction in Procedure-Related Losses |
-0.06% |
-0.06% |
Annual |
Source: National Center for Biotechnology Information
Key Summary for Payers:
- NIPT strategy results in moderately higher costs but reduces invasive procedures and complications.
- The strategy is likely cost-effective in the Brazilian private system, especially considering the reduction in amniocenteses.
Key Non-Invasive Prenatal Testing (NIPT) Market Insights Summary:
Regional Highlights:
- The North America is anticipated to hold a dominant 38.1% share by 2037, reinforced by advanced healthcare infrastructure and widespread adoption of molecular diagnostics
- Europe is set to represent 24.6% of the global non-invasive prenatal testing (NIPT) market share by 2037, stimulated by increasing adoption of prenatal genetic screening and growing maternal age
- The U.S. market is expected to increase at a CAGR of 9.77% from 2025 to 2037, mainly owing to the robust investments in advanced medical technologies.
- Japan is projected to capture nearly 3,8% of the global NIPT market share by 2037, supported by continuous technological advancements and high-tech hospital infrastructure.
Segment Insights:
- The consumables segment is forecast to command 85.6% of the global non-invasive prenatal testing (NIPT) market share by 2037, underpinned by the rising volume of pregnancies undergoing NIPT and the continuous demand for single-use reagents, assay kits, and sample preparation materials
- The maternal cell-free DNA (cfDNA) segment is expected to secure 38.7% of the global market share through 2037, fueled by its exceptional accuracy, early detection capabilities, and expanding adoption of sophisticated bioinformatics platforms
Key Growth Trends:
- Advancements in next-generation sequencing technologies
- Growing awareness of early prenatal genetic screening
Major Challenges:
- Regulatory Variability Across Global Markets
- High Cost of Testing
Key Players: Centogene N.V. (Germany), CRIFM Prenatal Medical Clinic (China), Eurofins LifeCodexx GmbH (Germany), MedGenome Labs Ltd. (India), NIPT Hiro Clinic (Japan), FALCO biosystems Ltd. (Japan), Biora Therapeutics, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina Inc. (U.S.), Laboratory Corporation of America Holdings (Labcorp) (U.S.), Natera Inc. (U.S.), Myriad Women's Health, Inc. (U.S.), QIAGEN (Netherlands), Quest Diagnostics (U.S.), CooperSurgical, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Baylor Genetics (U.S.), BGI (China), Lilac Insights (India), Neuberg Center for Genomic Medicine (India), Next Bioscience (South Africa), Progenics (U.S.), Sonic Healthcare (Australia), Thermo Fisher Scientific Inc. (U.S.), Yourgene Health (United Kingdom).
Global Non-Invasive Prenatal Testing (NIPT) Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2024 Market Size: USD 4.53 billion
- 2025 Market Size: USD 4.95 billion
- Projected Market Size: USD 14.59 billion by 2037
- Growth Forecasts: 9.42% CAGR (2025-2037)
Key Regional Dynamics:
- Largest Region: North America (38.1% Share by 2037)
- Fastest Growing Region: Europe
- Dominating Countries: United States, Canada, United Kingdom, Germany, China
- Emerging Countries: India, Japan, South Korea, Australia, Spain
Last updated on : 20 July, 2026
Non-Invasive Prenatal Testing (NIPT) Market - Growth Drivers and Challenges
Growth Drivers
- Advancements in next-generation sequencing technologies: The rapid advancements in next-generation sequencing (NGS) technologies are expected to push the sales of NIPT solutions. The advanced bioinformatics algorithms improve data interpretation, particularly in complex pregnancies, which is likely to increase the importance of non-invasive prenatal testing technologies.
In November 2024, the Frederick National Laboratory for Cancer Research held its last Biotech Connector event of the year. This was mainly focused on major progress in next-generation sequencing. Experts from the Frederick, Maryland area explained that this technology aids in quickly reading DNA and RNA, which helps scientists study large amounts of genetic material at once. Modern systems can now sequence 128 human genomes in 48 hours, showing how far the field has advanced since earlier methods. The event, co-hosted with the Frederick County Chamber of Commerce, also revealed how NGS is improving genetic testing and supporting better treatment decisions. - Growing awareness of early prenatal genetic screening: The growing awareness of the benefits of early prenatal genetic screening is expected to boost the sales of NIPT solutions in the years ahead. Both public and private initiatives are expected to accelerate the demand for non-invasive prenatal testing. In October 2025, the U.S. launched its first national genomic newborn screening initiative with a USD 14.4 million NIH grant. The multi-state BEACONS project, led by Mass General Brigham and Ariadne Labs, is set to study up to 30,000 newborns to assess the role of genomic sequencing in newborn screening.
- Expansion of healthcare infrastructure in emerging economies: The continuous expansion of healthcare infrastructure across emerging economies is creating substantial growth opportunities for non-invasive prenatal testing companies. Governments across high-potential economies are investing heavily in maternal healthcare services and diagnostic laboratories. The government of India announced the launch of Aarogya Setu 2.0 and other digital initiatives for the health sector in 2026. Thus, as healthcare infrastructure continues to modernize, the sales of non-invasive prenatal testing technologies are set to boom.
Challenges
- Regulatory Variability Across Global Markets: The regulatory variability across global markets is one of the key factors restraining the growth of the NIPT market. Each country has its own regulatory framework governing genetic testing. This lack of universally accepted regulations limits product approval and increases the cost for companies. Continuous innovations and research in NIPT are likely to lead to greater international harmonization of regulatory standards and clinical guidelines, contributing to the market growth in the years ahead.
- High Cost of Testing: The relatively high cost of non-invasive prenatal testing limits its adoption to some extent. The involvement of advanced technologies and specialized materials increases the final cost of testing. Many small-scale end users often refrain from investing in these solutions owing to budget constraints. However, mass production is expected to aid key players in increasing their sales and revenues.
Non-Invasive Prenatal Testing (NIPT) Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Period |
2025-2037 |
|
CAGR |
9.42% |
|
Base Year Market Size (2025) |
USD 4.53 billion |
|
Forecast Year Market Size (2037) |
USD 14.59 billion |
|
Regional Scope |
|
Non-Invasive Prenatal Testing (NIPT) Market Segmentation:
Product Segment Analysis
The consumables segment is projected to capture nearly 85.6% of the global non-invasive prenatal testing (NIPT) market share through 2037. Every test performed requires a continuous supply of single-use reagents, assay kits, sample preparation materials, and more. This directly drives the sales of consumables in non-invasive prenatal testing. The Observatory for Economic Complexity (OEC) estimates that in 2024, worldwide trade in laboratory reagents reached USD 44.9 billion, up 1.42% from USD 44.2 billion in 2023. Thus, as the number of pregnancies undergoing NIPT increases worldwide, the need for consumables is set to boom.
Method Segment Analysis
The maternal cell-free DNA (cfDNA) is anticipated to account for 38.7% of the global non-invasive prenatal testing market share throughout the forecast period. The exceptional accuracy and early detection capabilities are boosting the demand for maternal cell-free DNA (cfDNA) testing methods. The minimal risk to both the mother and fetus also increases the importance of maternal cell-free DNA. The vast adoption of sophisticated bioinformatics platforms further strengthens the reliability and clinical utility of maternal cfDNA testing.
Technology Segment Analysis
The next-generation sequencing (NGS) segment is expected to hold 40.6% of the global non-invasive prenatal testing market share by the end of 2037. Superior analytical performance and scalability are driving NGS demand. The accurately analyze cell-free fetal DNA (cfDNA) present in maternal blood is boosting the importance of next-generation sequencing. In June 2026, Roche launched AXELIOS 1, a new next-generation sequencing platform. Using SBX technology, it can complete whole-genome sequencing in a single day and deliver accurate research results within hours. Thus, technological innovations are set to double the sales of advanced NGS solutions.
Our in-depth analysis of the non-invasive prenatal testing market includes the following segments:
|
Segments |
Subsegments |
|
Product |
|
|
Application
|
|
|
Technology |
|
|
Pregnancy Risk |
|
|
End user |
|
|
Method |
|
|
Gestational Age
|
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Non-Invasive Prenatal Testing (NIPT) Market - Regional Analysis
North America Market Insights
North America is projected to capture 38.1% of the global non-invasive prenatal testing market share through 2037. The market growth is supported by advanced healthcare infrastructure and widespread adoption of molecular diagnostics. The strong awareness of prenatal genetic screening among healthcare professionals and expectant parents is also contributing to the overall market growth. Both the U.S. and Canada are most profitable marketplaces for non-invasive prenatal testing companies.
The U.S. non-invasive prenatal testing market is estimated to reach USD 3,435.70 million by 2037. The country’s highly developed healthcare system and extensive network of clinical laboratories drive the sales of NIPT technologies. The rise in public-private initiatives aimed at expanding prenatal care is likely to fuel the market growth. In September 2023, the U.S. Department of Health and Human Services, through the Health Resources and Services Administration, announced nearly USD 90 million in funding to support the White House plan addressing maternal health challenges. The effort aims to reduce maternal deaths and improve care for mothers and babies, especially in underserved communities.
Canada’s market for NIPTs is expected to increase at a CAGR of 9.31% from 2025 to 2037. The market growth is supported by increasing awareness of prenatal genetic screening and expanding access to molecular diagnostic services. The continuous improvements in maternal healthcare also drive the sales of non-invasive prenatal testing solutions. The growing maternal age and increased demand for early fetal health assessment are further contributing to the increasing sales of non-invasive prenatal testing technologies.
Europe Market Insights
Europe is projected to account for 24.6% of the global non-invasive prenatal testing (NIPT) market share through 2037. The region’s well-established healthcare systems and increasing adoption of prenatal genetic screening are driving the sales of NIPT solutions. The growing maternal age and rising awareness of prenatal health propel the demand for advanced NIPT technologies.
The UK non-invasive prenatal testing market is estimated at USD 244.31 million in 2025. The country’s strong clinical governance and widespread awareness of prenatal genetic screening drive the sales of advanced NIPT solutions. In 2026, the government announced an extra USD 55.35 million (£41 million) to improve safety at maternity and neonatal facilities. The supportive government initiatives directly drive the overall market growth.
Germany’s market for non-invasive prenatal testing is projected to reach USD 556.47 million by 2037. The country's extensive network of hospitals and specialized prenatal diagnostic centers fuels the sales of non-invasive prenatal testing solutions. The country’s developed healthcare infrastructure also contributes to the increasing application of NIPT technologies. With continued investments in precision medicine, the market is set to witness a boom in the years ahead.
Asia Pacific excluding Japan Market Insights
Asia Pacific excluding Japan is anticipated to hold 20.8% of the global non-invasive prenatal testing market by the end of the forecast period. The increasing investments in advanced healthcare infrastructure and expanding access to molecular diagnostics are propelling the sales of non-invasive prenatal testing solutions. China, India, and South Korea are some of the leading marketplaces for non-invasive prenatal testing companies.
China’s non-invasive prenatal testing market is set to reach USD 920.83 million by 2037. The continuous investments in healthcare modernization are boosting the trade of non-invasive prenatal testing technologies. The country has developed a strong molecular diagnostics ecosystem, with numerous domestic biotechnology companies. Further, with the expanding diagnostic infrastructure and rising public awareness, China is expected to remain the leading non-invasive prenatal testing market in Asia Pacific.
India’s market for non-invasive prenatal testing is estimated to expand at a 10.14% CAGR between 2025 and 2037. The expanding healthcare infrastructure and rapid growth in molecular diagnostic services are propelling the sales of non-invasive prenatal testing technologies. The Genome India Mission has already sequenced the genomes of more than 10,000 people and is moving ahead with the goal of creating one of the world’s largest genomic databases. Supportive government initiatives and policies are creating a profitable ecosystem for NIPT companies.
Japan Market Insights
Japan’s non-invasive prenatal testing (NIPT) market is projected to be valued at USD 220.33 million in 2025. The country's technologically advanced healthcare infrastructure is directly fueling the sales of non-invasive prenatal testing solutions. The increasing adoption of precision medicine and strong expertise in molecular diagnostics are boosting the demand for non-invasive prenatal testing solutions. The country's growing maternal age and rising focus on improving pregnancy outcomes are also contributing to increasing demand for early and accurate prenatal genetic screening. The supportive government policies and initiatives are further opening high-earning opportunities for NIPT companies.
The Japanese government under the Kishida administration has introduced several measures to support mothers and child-rearing as part of its efforts to address the declining birthrate. Key initiatives include expanding child allowances with higher payments for younger children and larger families, increasing financial assistance for childbirth, and providing subsidies for low-income pregnant women. These policies aim to reduce the financial and career-related burdens on mothers, indirectly driving sales of NIPT solutions.
Japan Hydrotalcite Market Size and Forecast
|
Report Attribute |
Details |
|
Base Year Market Size (2024) |
USD 203.95 million |
|
Forecast Year Market Size (2037) |
USD 554.43 million |
|
CAGR (2025-2037) |
7.99% |
Key Non-Invasive Prenatal Testing (NIPT) Market Players:
- Centogene N.V. (Germany)
- CRIFM Prenatal Medical Clinic (China)
- Eurofins LifeCodexx GmbH (Germany)
- MedGenome Labs Ltd. (India)
- NIPT Hiro Clinic (Japan)
- FALCO biosystems Ltd. (Japan)
- Biora Therapeutics, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Illumina Inc. (U.S.)
- Laboratory Corporation of America Holdings (Labcorp) (U.S.)
- Natera Inc. (U.S.)
- Myriad Women's Health, Inc. (U.S.)
- QIAGEN (Netherlands)
- Quest Diagnostics (U.S.)
- CooperSurgical, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Baylor Genetics (U.S.)
- BGI (China)
- Lilac Insights (India)
- Neuberg Center for Genomic Medicine (India)
- Next Bioscience (South Africa)
- Progenics (U.S.)
- Sonic Healthcare (Australia)
- Thermo Fisher Scientific Inc. (U.S.)
- Yourgene Health (United Kingdom)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Centogene N.V. strengthens its position in the market through its expertise in rare disease diagnostics, genomic sequencing, and bioinformatics. The company leverages advanced next-generation sequencing (NGS) technologies and proprietary data analytics to deliver high-quality prenatal genetic testing services. Its extensive genomic database, international laboratory network, and collaborations with healthcare providers support accurate and timely test results. Centogene continues to expand its precision medicine portfolio through investments in genomic research and digital diagnostic capabilities.
- CRIFM Prenatal Medical Clinic is a specialized provider of prenatal diagnostic and fetal medicine services, offering non-invasive prenatal testing as part of comprehensive maternal healthcare. The clinic focuses on integrating advanced genetic screening technologies with expert prenatal counseling and fetal assessment. Its competitive strength lies in personalized patient care, experienced clinical specialists, and adoption of modern molecular diagnostic techniques. Continuous improvements in prenatal screening services and patient-centered care support its position within China's prenatal diagnostics market.
- Eurofins LifeCodexx GmbH is a prominent player in the European market, benefiting from the extensive laboratory network and scientific expertise of the Eurofins Group. The company offers validated cell-free DNA screening solutions supported by advanced sequencing technologies and rigorous quality standards. Its strong collaborations with hospitals, gynecologists, and diagnostic laboratories have expanded market reach across Europe. Ongoing investments in molecular diagnostics and laboratory innovation reinforce its competitive position in prenatal genetic testing.
- MedGenome Labs Ltd. has established a strong presence in the NIPT market by combining advanced genomics expertise with an expanding diagnostic laboratory network across India and international markets. The company utilizes next-generation sequencing technologies to provide accurate prenatal genetic screening supported by comprehensive genetic counseling services. Strategic collaborations with hospitals, fertility clinics, and healthcare providers have strengthened its market penetration. Continued investments in genomic research and precision diagnostics further enhance its competitive position.
- NIPT Hiro Clinic has built a strong reputation in Japan's prenatal diagnostics market by specializing in non-invasive prenatal testing and maternal-fetal healthcare services. The clinic offers advanced cell-free DNA screening supported by modern sequencing technologies and individualized genetic counseling. Its focus on patient education, accurate diagnosis, and high-quality prenatal care differentiates it within the market. Continuous adoption of advanced genomic technologies and expansion of specialized prenatal services support its competitive standing in Japan.
Below is the list of the key players, among several others, operating in the global non-invasive prenatal testing market:
The strong presence of regional and international companies characterizes the non-invasive prenatal testing market. Leading companies are focused on technological innovations to introduce next-gen solutions. They are also engaging in strategic collaborations with others to enhance their product offerings. Some gigantic companies are exploring opportunities across high-potential economies to earn lucrative returns. Both organic and inorganic marketing strategies are projected to double the revenues of key players during the study period.
Corporate Landscape of the Global NIPT Market:
Recent Developments
- In May 2024, Natera announced an upgraded version of its Panorama prenatal test. Using its new sequencing technology, the test now has proven results even in samples with low fetal fraction, with a no-call rate of 0.5%.
- In June 2025, BGI Genomics and its partner Prom-Test Laboratories marked the first local rollout of the Non-Invasive Prenatal Testing project in Armenia. Started in 2024 after a successful technology transfer, the project aims to make advanced prenatal testing more accessible and improve care for expectant mothers across the country.
- Report ID: 6309
- Published Date: Jul 20, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2025-2037
Copyright @ 2026 Research Nester. All Rights Reserved.
